112965-21-6 Usage
Description
Calcipotriene, also known as Calcipotriol, is a topical vitamin D3 derivative effective in the treatment of psoriasis vulgaris. It is a white crystalline solid that acts by binding to vitamin D3 receptors in the skin keratinocytes, promoting cell differentiation and reducing cell proliferation. With a significantly lower effect on calcium metabolism compared to calcitriol, Calcipotriene is a promising antipsoriatic agent.
Uses
Used in Dermatology:
Calcipotriene is used as an antipsoriatic agent for the treatment of localized psoriasis. It is one of the most effective non-glucocorticoid topical drugs for this purpose, marketed under the trade names Dovonex and Daivonex.
Used in Combination Therapy:
Calcipotriene is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients. This combination enhances the therapeutic effects and provides a more comprehensive treatment approach.
Used in Off-Label Applications:
Calcipotriene has various off-label applications as an alternative therapy for a range of dermatologic diseases, showcasing its versatility and potential in addressing different skin conditions beyond its primary use in psoriasis treatment.
Originator
Leo Denmark (Denmark)
Indications
Calcipotriene (Dovonex), a synthetic vitamin D3 derivative,
is indicated for the treatment of moderate plaque
psoriasis. Its mechanism of action is unknown, although
it competes for calcitriol receptors on keratinocytes and
normalizes differentiation. It also has a variety of immunomodulatory
effects in the skin. Although the drug
can cause local irritation, the most serious toxicities are
hypercalciuria and hypercalcemia, which are usually reversible.
Preparation
A convergent approach for the total synthesis of calcipotriol (brand name: Dovonex), a proven Vitamin D analog used for the treatment of psoriasis, and medicinally relevant synthetic analogs is described.A Synthesis of calcipotriol via a Key Electroreductive Cross-coupling ApproachCalcipotriol is currently the most successful VitD analog and is prescribed for the treatment of psoriasis, an autoimmune skin disease.
Manufacturing Process
(1S,3R)-Bis-(t-butyldimethylsilyloxy)-(20S)-formyl-9,10-secopregna(5E,7E,10
(19))triene (Calverley Tetrahedron 43.4609 (1967) and (cyclopropyl)(tri-phenylphoshoranylidene)ketone are stirred in dimethyl sulfoxide under
nitrogen. The reaction mixture is then diluted at room temperature with ethyl
acetate and washed with common salt solution. The organic phase is dried on
sodium sulfate and filtered. After removal of the solvent, the residue is filtered
with toluene through silica gel. Evaporation of the solvent and gradient
chromatography (toluene/hexane (1:1)-toluene) of the residue on silica gel
yield (5E,7E,22E),(1S,3R)-1,3-bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-
9,10-secochola-5,7,10(19),22-tetraene-24-one.(5E,7E,22E),(1S,3R)-1,3-Bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-9,10-
secochola-5,7,10(19),22-tetraene-24-one in tetrahydrofuran and methanol are
mixed with a 0.4 M methanol CeCl3·7H2O solution. Sodium borohydride is
added by portions under nitrogen with ice cooling. The suspension is stirred
with ice cooling and then put into ice/common salt solution. The aqueous
phase is extracted with ethyl acetate, the organic phase is washed neutral
with water and dried on sodium sulfate. Filtration and removal of the solvent
yield oil. By chromatography on silica gel with ethyl acetate/hexane (1:9). The
(5E,7E,22E),(1S,3R,24S)-1,3-bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-
9,10-secochola-5,7,10(19),22-tetraene-24-ol is obtained.(5E,7E,22E),(1S,3R,24S)-1,3-Bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-
9,10-secochola-5,7,10(19),22-tetraene-24-ol is dissolved in toluene and after
addition of anthracene and 1 drop of triethylamine it is radiated at room
temperature with a high pressure mercury vapor lamp (Heraeus TQ 150)
through Pyrex glass. The reaction mixture is concentrated by evaporation and
the residue a mixture of (5Z,7E,22E),(1S,3R,24S)-1,3-bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-
24-ol and anthracene - is directly reacted with tetrabutylammonium fluoride.(5Z,7E,22E),(1S,3R,24S)-1,3-Bis-(t-butyldimethylsilyloxy)-24-cyclopropyl-
9,10-secochola-5,7,10(19),22-tetraene-24-ol in tetrahydrofuran is kept with a
1 M solution of tetrabutylammonium fluoride in tetrahydrofuran under
nitrogen. For working up, the cooled reaction mixture is poured into cold
sodium bicarbonate solution and then extracted with ethyl acetate. After
drying of the organic phase on sodium sulfate, filtration and evaporation of
the solvent yields a resin-like residue. Chromatography on silica gel with ethyl
acetate/hexane (2:1) yields (5Z,7E,22E),(1S,3R,24S)-24-cyclopropyl-9,10-
secochola-5,7,10(19),22-tetraene-1,3,24-triol.
Therapeutic Function
Antipsoriatic
Biological Activity
Vitamin D 3 analog that displays minimal effects on calcium homeostasis. Regulates cell differentiation and proliferation; exhibits antiproliferative activity against human HL-60, HL60/MX2, MCF-7, T47D, SCC-25 and mouse WEHI-3 cancer cell lines.
Biochem/physiol Actions
Calcipotriol, a synthetic derivative of calcitriol or Vitamin D, is used in the treatment of psoriasis and marketed under the trade name Dovonex. It has comparable affinity with calcitriol (Vit. D) for the Vitamin D receptor (VDR), while being less than 1% as active as the calcitriol in regulating calcium metabolism. VDR belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. Binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation-related genes.
Pharmacology
Calcipotriene (Dovonex) enhances the effectiveness of ultraviolet B
(UVB) but also increases photosensitivity in UVB-treated patients. Ultraviolet
light, 6% salicylic acid, 12% lactic acid, hydrocortisone valerate 0.2% ointment,
and tazarotene (Tazorac) gel degrade calcipotriene (Dovonex). Halobetasol
ointment and 5% tar gel are compatible with Calcipotriene (Dovonex).
A British study found calcipotriene (Dovonex) to be safe and effective in a
pediatric population over the age of 3, although it is not approved by the FDA.
Check Digit Verification of cas no
The CAS Registry Mumber 112965-21-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,9,6 and 5 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 112965-21:
(8*1)+(7*1)+(6*2)+(5*9)+(4*6)+(3*5)+(2*2)+(1*1)=116
116 % 10 = 6
So 112965-21-6 is a valid CAS Registry Number.
InChI:InChI=1/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24?,25-,26+,27-/m1/s1
112965-21-6Relevant articles and documents
Calcipotriol intermediate compound and preparation method thereof
-
, (2017/01/02)
The invention discloses a calcipotriol intermediate compound and a preparation method thereof. The structure of the compound is represented by general formula I shown in the description. In the general formula I, R1 is selected from a carbobenzoxy group (Cbz), a trimethylsilyl group (TMS), a triethylsilyl group (TES), a t-butyldimethylsilyl group (TBDMS), a triisopropylsilyl group (TIPS), a t-butyl-diphenylsilyl group (TBDPS) or a methoxymethyl group (MOM); and R2 is one of groups shown in the description.
EPIMERIZATION BY STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES
-
Page/Page column 11-12, (2009/06/27)
A method for epimerization process of C-24 ketones to desired C-24 alcohol by stereo selective reduction using chiral borane reducing agents in the presence of chiral auxillary such as (R)-2-methyl-CBS-oxazaborolidine for the preparation of calcipotriene intermedites and its process to calcipotriene.
Method for preparing analogue of vitamin D
-
Page/Page column 11, (2008/06/13)
A method for preparing analogues of C1,C24-dihydroxy-vitamin D is disclosed. Especially the method for preparing calcipotriol and tacalcitol from a starting material of Vitamin D2 is disclosed here. Calcipotriol (compound 1(a)) and tacalcitol (compound 1(b)) can be synthesized by the method of the present invention. Moreover, only nine steps are needed for the synthesis of calcipotriol using the method. Likewise, only ten steps are needed for the synthesis of tacalcitol by the present method. Hence, the present method, with less process steps and higher yields, represents an improvement over the conventional methods.